CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced today that the Trizytek TM (liprotamase) Phase 3 efficacy study results will be presented at oral and poster sessions at the 2008 North American Cystic Fibrosis Conference (NACFC) in Orlando, FL on October 23 and 24. Trizytek is a non-porcine derived enzyme replacement therapy for patients with pancreatic insufficiency. The Phase 3 Trizytek efficacy results will be presented by Dr. Drucy Borowitz, Professor of Clinical Pediatrics, State University of New York, Director, Cystic Fibrosis Center, Women and Children’s Hospital of Buffalo and principal investigator for the Trizytek Phase 3 trials.
